Vertex Announces U.S. FDA Approval for KALYDECO® (ivacaftor) to Treat Eligible Infants With CF Ages 1 Month and OlderBusiness Wire • 05/03/23
Vertex Pharmaceuticals (VRTX) Q1 Earnings and Revenues Surpass EstimatesZacks Investment Research • 05/01/23
Vertex Pharmaceuticals Keeps Its Outlook Despite Beating Views, And DivesInvestors Business Daily • 05/01/23
Strength Seen in Vertex (VRTX): Can Its 5.0% Jump Turn into More Strength?Zacks Investment Research • 04/28/23
Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 Through 5 With Certain MutationsBusiness Wire • 04/26/23
Vertex to Present at the Bank of America Securities 2023 Health Care Conference on May 9Business Wire • 04/25/23
Earnings Preview: Vertex Pharmaceuticals (VRTX) Q1 Earnings Expected to DeclineZacks Investment Research • 04/24/23
Have $1,000? 2 Explosive Growth Stocks to Buy and Hold No Matter What the Market Does NextThe Motley Fool • 04/20/23